Mono PharmacareShare price, financial results, shareholding and management
- Market cap
- ₹18 cr
- Stock P/E
- 50.5peers 15.1
- Book value
- ₹17.9
- Price to book
- 0.56
- EV / operating profit
- 18.4
- Market cap to sales
- 0.11
- ROCE · FY26
- 4.5%
- ROE · FY26
- 1.1%
- ROE, 3-year average
- 7.1%
- Operating margin · FY26
- 2.4%peers 10.2%
- Sales growth, 3 years
- 71.2%
- Profit growth, 3 years
- -29.5%
- Debt to equity
- 1.79peers 0.34
- Borrowings
- ₹56.5 cr
- Interest cover
- 1.2×
- Cash from business / op. profit
- 58%
- Debtor days
- 165
- Pledged
- 0.00%
- Promoter holding
- 56.72%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 529
- 52-week high / low
- ₹22 / ₹8
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Mono Pharmacare share price chart
Close on 18 Nov 2026 · -2.44% on the day · Vol 4,000
Daily prices to 18 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 18 Nov 2026
- 1 month
- +12.4%
- 3 months
- +22.0%
- 6 months
- -13.0%
- 1 year
- -51.3%
- Traded a day, 20 days
- ₹0.01 cr
- Taken for delivery
- 90%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | -2% | -89% |
| 3 years, a year | +71% | -30% |
| Latest half, H2 FY26 | +22% | -55% |
Mono Pharmacare revenue and profit growth
Half-yearly results · Profit and lossSales have grown very fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.
Mono Pharmacare half-yearly results
SME companies report every six months · ₹ crore
| H2FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 35 | 67 | 56 | 87 | 81.18 | 66.29 | 99.40 |
| Expenses | 33 | 63 | 53 | 82 | 78.28 | 64.52 | 97.18 |
| Operating profit | 2 | 4 | 2 | 5 | 2.90 | 1.77 | 2.22 |
| OPM | 6.0% | 6.0% | 4.4% | 5.0% | 3.6% | 2.7% | 2.2% |
| Interest | 1 | 2 | 2 | 2 | 2.46 | 1.61 | 1.71 |
| Depreciation | 0 | 0 | 0 | 0 | 0.06 | 0.06 | 0.06 |
| Profit before tax | 1 | 2 | 1 | 3 | 1.31 | 0.12 | 0.46 |
| Net profit | 1 | 2 | 1 | 2 | 0.73 | 0.02 | 0.33 |
Mono Pharmacare profit and loss
Full years to March, FY23 to FY26 · ₹ crore, consolidated where reported
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Sales | 33 | 122 | 168.34 | 165.69 |
| Expenses | 31 | 116 | 160.71 | 161.70 |
| Operating profit | 2 | 6 | 7.64 | 3.99 |
| OPM | 7.0% | 5.0% | 4.5% | 2.4% |
| Other income | 0 | 0 | 0.98 | 0.01 |
| Interest | 1 | 3 | 4.03 | 3.32 |
| Depreciation | 0 | 0 | 0.13 | 0.11 |
| Profit before tax | 1 | 3 | 4.46 | 0.58 |
| Tax rate | 0.0% | 33.3% | 30.7% | 39.7% |
| Net profit | 1 | 2 | 3.09 | 0.35 |
| EPS ₹ | 0.76 | 1.38 | 1.75 | 0.20 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% |
The years to FY24 come rounded to the nearest crore in the source.
Earnings per share before FY26 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Mono Pharmacare profitability
Margins and returns on capitalLast year the company kept less from each rupee of sales than the year before. It earns a low return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Operating margin | 7.0% | 5.0% | 4.5% | 2.4% |
| Tax rate | 0.0% | 33.3% | 30.7% | 39.7% |
| ROCE | · | 9.8% | 11.0% | 4.5% |
| ROE | · | 9.8% | 10.4% | 1.1% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% |
Mono Pharmacare debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. Its loans are now larger than its own money. Last year the business brought in more cash than it showed as profit. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Mono Pharmacare balance sheet
At each 31 March · ₹ crore
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Equity capital | 12 | 18 | 17.67 | 17.67 |
| Reserves | 1 | 10 | 13.53 | 13.88 |
| Net worth | 13 | 28 | 31.20 | 31.55 |
| Borrowings | 40 | 41 | 53.56 | 56.50 |
| Other liabilities | 10 | 12 | 25.29 | 34.24 |
| Total liabilities | 63 | 81 | 110.05 | 122.29 |
| Fixed assets | 1 | 1 | 0.99 | 0.88 |
| Capital work in progress | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 |
| Other assets | 61 | 80 | 109.06 | 121.41 |
| Receivables | · | · | 41.89 | 74.94 |
| Inventory | · | · | 55.39 | 42.43 |
| Cash | · | · | 0.70 | 0.98 |
| Trade payables | · | · | 18.80 | 29.22 |
Mono Pharmacare cash flow
₹ crore
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Cash from operations | -40 | -9 | -4.30 | 2.30 |
| Cash from investing | -1 | 0 | -0.23 | 0 |
| Cash from financing | 41 | 8 | 4.86 | -2.01 |
| Net cash flow | 0 | -1 | 0.33 | 0.29 |
| Capital spending | · | · | 0.23 | 0 |
Working capital
Days
| FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|
| Debtor days | 241 | 94 | 91 | 165 |
| Inventory days | 408 | 139 | 133 | 99 |
| Days payable | 87 | 32 | 45 | 68 |
| Cash conversion cycle | 563 | 202 | 179 | 196 |
| Working capital days | 299 | 131 | 120 | 126 |
Mono Pharmacare peers and competitors
Listed SME companies in the same industryBy sales, Mono Pharmacare is number 6 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Sat Kartar Life | 220 | 12.9 | 201 | 17 | 12.0% | 0.03 |
| Infinium Pharmachem | 471 | 38.7 | 190 | 12.2 | 11.4% | 0.19 |
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 18 | 50.5 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| Median of the 10 others | 187 | 15.1 | 139 | 9.3 | 10.2% | 0.34 |
Mono Pharmacare shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Mono Pharmacare shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 23 | Dec 23 | Mar 24 | Sep 24 | Mar 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|
| Promoters | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% |
| Foreign investors (FIIs) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | - | - |
| Indian institutions (DIIs) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | - | - |
| HNIs (over ₹2 lakh each) | 23.64% | 24.43% | 26.54% | 25.09% | 25.22% | 23.71% | 22.42% |
| Small holders (up to ₹2 lakh) | 14.49% | 12.77% | 10.15% | 10.18% | 10.37% | 10.76% | 10.86% |
| Companies and others | 5.15% | 6.08% | 6.59% | 8.01% | 7.69% | 8.81% | 10.00% |
| Number of shareholders | 621 | 528 | 418 | 463 | 478 | 514 | 529 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Mono Pharmacare latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹99.4 cr (+22%), net profit ₹0.3 cr (-55%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 56.72%.
Mono Pharmacare announcements
33 on record, latest first; each opens the filing on the exchange
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 30, 2026PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Record Datethat Record date for the purpose of Meeting is 23-Sep-2026PDF ↗
- Updates'Board comment on fine levied'PDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 30, 2026PDF ↗
- Outcome of Board MeetingHeld on September 03, 2026PDF ↗
- General UpdatesRegarding the re-appointment of Secretarial Auditor of the companyPDF ↗
- Change in AuditorsOf the companyPDF ↗
- Resignation of Director/KMP/SMPResignation of Director/KMP/SMPPDF ↗
- Outcome of Board Meeting, the financial results for the period ended March 31, 2026PDF ↗
- ResignationOf Mr Rahul Joshi as Company Secretary & Compliance Officer of the company w.e.f. July 01, 2026PDF ↗
Mono Pharmacare annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Mono Pharmacare share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Mono Pharmacare's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,76,68,564 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY23 to FY26.
- iPrices run to the close on 9 Oct 2026, from the exchange's daily figures.
Questions people ask about Mono Pharmacare
What does Mono Pharmacare do?
Mono Pharmacare is an SME company listed on NSE Emerge, in pharmaceuticals & biotechnology.
What is the share price of Mono Pharmacare?
₹10 at the close on 18 Nov 2026, from the exchange's daily figures.
What is the market cap of Mono Pharmacare?
₹18 cr at the close on 18 Nov 2026, on 1,76,68,564 shares.
What is the P/E of Mono Pharmacare?
50.5 times FY26 profit at the close on 18 Nov 2026 (our arithmetic).
What are Mono Pharmacare's revenue and profit?
Revenue ₹166 cr and profit after tax ₹0 cr in FY26.
Who are the promoters of Mono Pharmacare?
The promoter group; promoters held 56.72% at 31 March 2026.
What is Mono Pharmacare's website?
monopharmacareltd.com
More SME companies like Mono Pharmacare
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Sunrest LifescienceSUNREST · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹18 cr
- Walpar NutritionsWALPAR · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2021Market cap ₹19 cr
- Goldline PharmaceuticalGLPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹28 cr
- Dipna PharmachemDPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹11 cr
- Medicamen OrganicsMEDIORG · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹35 cr
- Jfl Life SciencesJFLLIFE · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2022Market cap ₹39 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2023 →
Built from 33 exchange announcements, 7 shareholding patterns and 4 years of reported results. Every figure carries its source; where the documents are silent, the page says so.